Identification and structure-activity relationship analysis of minimal fusion inhibitors targeting measles virus F

Kazuya Kobayashi1, Yuki Yamaguchi1, Mizuki Itahara1

  • 1Laboratory of Medicinal Chemistry, Kyoto Pharmaceutical University Yamashina-ku Kyoto 607-8412 Japan soishi@mb.kyoto-phu.ac.jp +81 75 595 4635.

Insights

Researchers optimized a peptide to inhibit measles virus (MV) fusion, identifying a shorter derivative with potent antiviral activity. This work clarifies the structural basis for fusion inhibitors, aiding in measles elimination strategies.

Area of Science:

  • Virology
  • Structural Biology
  • Drug Discovery

Background:

  • Measles outbreaks persist despite vaccination, necessitating complementary antiviral strategies.
  • Previous work identified an anti-measles virus (MV) peptide targeting the fusion (F) protein's HR1-HR2 interaction.

Purpose of the Study:

  • To optimize an existing anti-MV peptide by minimizing its sequence while retaining antiviral efficacy.
  • To elucidate the structure-activity relationships of HR2-derived peptides targeting MV fusion.

Main Methods:

  • Structure-activity relationship (SAR) analyses of HR2-derived peptides.
  • Thermal stability assays using HR1-40 and a novel HR1Y variant.
  • Molecular modeling of peptide-protein interactions.

Main Results:

  • Both hydrophobic and polar residues in HR2 peptides are critical for HR1 interaction.
  • A minimized peptide derivative demonstrated potent antiviral activity.
  • Molecular modeling provided structural insights into the HR1-HR2 interface.

Conclusions:

  • Rational optimization of HR2-derived peptides is supported by understanding structural determinants.
  • These findings contribute to developing novel antiviral agents for measles elimination.